Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up · inside the Ichimoku cloud · RSI 100 (overbought) · MACD below its signal · at its 52-week high
None of the 29 investors followed here reported a position in INLB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No insider transactions reported for INLB.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | -73.7 | -30.0 | -14.3 | -33.3 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −94.7% |
| 2023 | 14.4 | -3.5 | -27.5 | -49.0 | 37.3 | -23.6 | -54.5 | -43.3 | -0.7 | -59.9 | -56.4 | -20.8 | −98.5% |
| 2022 | 1.8 | -2.7 | 22.7 | -18.5 | -10.9 | -18.4 | -18.8 | -13.8 | -29.5 | -44.3 | 45.5 | -60.9 | −88.7% |
| 2021 | 42.1 | 22.9 | 2.0 | -3.1 | 2.1 | -7.2 | -15.9 | -20.3 | -26.4 | -2.5 | -30.3 | 2.8 | −43.7% |
| 2020 | 21.1 | 6.1 | -18.0 | -17.0 | 30.1 | -9.3 | -2.0 | 8.3 | 44.2 | -16.7 | 72.0 | -8.4 | +107.4% |
| 2019 | -13.1 | -6.0 | 5.9 | 46.7 | -31.8 | -11.1 | -18.8 | -7.7 | -7.0 | -42.7 | 2.5 | -42.1 | −81.7% |
| 2018 | -21.4 | -9.1 | 60.0 | 0.0 | -12.6 | 0.1 | -20.7 | 25.2 | -20.9 | 9.1 | 45.8 | 48.6 | +85.7% |
| 2017 | 4.0 | 11.5 | -13.8 | -8.2 | -18.3 | -20.0 | 3.3 | -11.3 | 9.1 | -33.3 | 711.5 | -13.7 | +180.0% |
| 2016 | 15.4 | -18.7 | 72.1 | -30.5 | -4.2 | -28.9 | -1.5 | -28.6 | -7.1 | -7.7 | -33.3 | 25.0 | −61.5% |
| 2015 | 15.4 | -20.0 | -16.8 | 20.1 | 0.0 | 33.3 | 0.0 | 25.0 | -10.3 | -22.0 | -28.6 | 30.0 | −0.0% |
| 2014 | 45.0 | 6.9 | 9.6 | -26.5 | -11.6 | -1.9 | -7.7 | -25.0 | 0.0 | -6.7 | -1.1 | -6.0 | −35.0% |
| 2013 | -32.0 | -51.0 | -19.5 | 24.3 | 96.0 | -10.2 | -31.8 | -10.0 | -44.4 | 33.3 | -10.0 | 11.1 | −73.3% |
| 2012 | 40.6 | 6.7 | -0.4 | -39.3 | -26.9 | 5.7 | -53.6 | 53.8 | -31.4 | 80.3 | -24.2 | −53.1% |
No member of Congress has disclosed a INLB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
No recent headlines.